Synonyms |
3-Hydroxycotinine; Cotinine; Nicotine; Nicotine and Cotinine |
SPECIMEN REQUIREMENTS |
|
Container Type |
Red top tube (plain) |
Supply Item Number |
1372 |
Specimen Type |
Serum |
Preferred Volume |
4 mL |
Emergency Minimum Volume |
1 mL |
Specimen Processing |
Separate serum or plasma from cells ASAP or within 2 hours of collection and transfer to a standard PAML aliquot tube. |
Store and Transport |
Refrigerated |
Stability |
Room Temp 1 week Refrigerated 2 weeks Frozen (-20 °C) 1 month |
Unacceptable Condition |
Plasma or whole blood collected in lt. blue (sodium citrate). Specimens exposed to more than 3 freeze/thaw cycles |
Alternate Specimens |
Green (sodium heparin), lavender (EDTA), pink (K2EDTA), or gold, brick, SST, or corvac (serum separator tube) |
Reference Laboratory |
PAML |
CPT Codes |
80323, (HCPCS G0480) |
Interface Order Code |
83887.Z10 |
Billing Code |
NICMSP |
Test Schedule |
Tue, Thu |
Turnaround Time |
1-5 days |
Method |
Tandem Mass Spectrometry |
Reference Ranges |
Title | Descriptor | Ranges | Units | Nicotine | Non-smoker | < 2 | ng/mL | Cotinine | Non-smoker | < 5 | ng/mL | 3-OH-Cotinine | Non-smoker | < 10 | ng/mL | | > 5 ng/mL Nicotine indicates use of tobacco products and or nicotine replacement therapy. | > 100 ng/mL Cotinine indicates use of tobacco products and or nicotine replacement therapy. Cotinine is the major metabolite of nicotine. | > 100 ng/mL of 3-OH Cotinine indicates use of tobacco products and/or nicotine replacement therapy. |
|
Compliance Remarks |
This test was developed and its performance characteristics determined by PAML. The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. PAML is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing. |
Notes |
Useful for monitoring tobacco use, as well as, monitoring patients on nicotine-replacement therapy for concurrent use of tobacco products. |